AbCellera-Discovered Bamlanivimab Together With Etesevimab Authorized As The First And Only Antibody Therapy For Emergency Use In COVID-19 Patients Under The Age Of 12 [TheStreet.com]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: TheStreet.com
Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12, including neonates (infants The expanded EUA is based on data from the BLAZE-1 Phase 2/3 clinical trial studying bamlanivimab and etesevimab administered together for the treatment of pediatric and infant patients with mild to moderate COVID-19 and who are at high risk for severe disease progression. The median time to complete symptom resolution as recorded in a trial specific daily symptom diary was 7 days for subjects treated with bamlanivimab 700 mg and etesevimab 1,400 mg and 5 days for subjects treated with weight-based dosing of bamlanivimab and etesevimab. No subject died or required hospitalization due to COVID-19. Pseudovirus and authentic virus studies conducted by AbCellera's partner, Eli Lilly and Company (Lilly), demonstrate that bamlanivimab and etesevimab together retain neutral
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin Disorder [Yahoo! Finance]Yahoo! Finance
- DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity Prevention and Management [Yahoo! Finance]Yahoo! Finance
- Insiders Are Dumping These 10 Healthcare Stocks [Yahoo! Finance]Yahoo! Finance
- Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33% [Yahoo! Finance]Yahoo! Finance
- Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial [BNN Bloomberg (Canada)]BNN Bloomberg
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 3/28/24 - Form PX14A6G
- 3/28/24 - Form PX14A6G
- 3/28/24 - Form PX14A6G
- LLY's page on the SEC website